Geron Corp.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Geron Corp.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
/ 
Frequently asked questions
To buy Geron Corp. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Geron Corp. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Geron Corp. is GERN:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Geron Corp. has its primary listing on NASDAQ. You can trade Geron Corp. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Geron Corp. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Geron Corp. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Geron Corp..